Discovery of 2-(4-chloro-3-(trifluoromethyl)phenyl)-n-(4-((6,7-dimethoxyquinolin-4-yl )oxy)phenyl)acetamide (CHMFL-KIT-64) As a Novel Orally Available Potent Inhibitor Against Broad Spectrum Mutants of C-Kit Kinase for Gastrointestinal Stromal Tumors

Yun Wu,Beilei Wang,Junjie Wang,Shuang Qi,Fengming Zou,Ziping Qi,Feiyang Liu,Qingwang Liu,Cheng Chen,Chen Hu,Zhenquan Hu,Aoli Wang,Li Wang,Wenchao Wang,Tao Ren,Yujiao Cai,Mingfeng Bai,Qingsong Liu,Jing Liu

DOI: https://doi.org/10.1021/acs.jmedchem.9b00280

IF: 8.039

2019-01-01

Journal of Medicinal Chemistry

Abstract:Starting from our previously developed c-KIT kinase inhibitor CHMFL-KIT-8140, through a type II kinase inhibitor binding element hybrid design approach, we discovered a novel c-KIT kinase inhibitor compound 18 (CHMFL-KIT-64), which is potent against c-KIT wt and a broad spectrum of drug-resistant mutants with improved bioavailability. 18 exhibits single-digit nM potency against c-KIT kinase and c-KIT T670I mutants in the biochemical assay and displays great potencies against most of the gain-of-function mutations in the juxtamembrane domain, drug-resistant mutations in the ATP binding pocket (except V654A), and activation loops (except D816V). In addition, 18 exhibits a good in vivo pharmacokinetic (PK) profile in different species including mice, rats, and dogs. It also displays good in vivo antitumor efficacy in the c-KIT T670I, D820G, and Y823D mutant-mediated mice models as well as in the c-KIT wt patient primary cells which are known to be imatinib-resistant. The potent activity against a broad spectrum of clinically important c-KIT mutants combining the good in vivo PK/pharmacodynamic properties of 18 indicates that it might be a new potential therapeutic candidate for gastrointestinal stromal tumors.